I would just say do more of the same. I think Canada is actually well situated to deal with this in many ways. I think there's sort of an advertising problem, if I can say that. With the hypnotic medications we use, if you look at the February 2012 British Medical Journal, you'll see there's a sixfold increase in cancer in people who are using hypnotics on a regular basis. That's a significant concern.
With Canada, we have a lot of things that were really established after I got started. The natural health products registry or directorate, as part of Health Canada, I think is a great idea. Likely you could just focus more on it and get it more disciplined in its focus and get a faster time to approval. It's the approval process that is really the valley of death. It's not so much the patent costs. The patent costs are fixed and you can manage those to a certain degree, but really what you have to do is get a product on the market.
So I think Canada has a unique opportunity because of the way Health Canada could regulate this to get the product out there a little bit faster. Health Canada approval is taken seriously by many other countries—Korea and the U.K, for example. If you're approved with an NPN in Canada, you'll make it faster into the other regulatory environments. So I think just more of that would be good.
I just think the other part is the education of physicians in the way we've talked about, sort of as an entrepreneur. How are they going to raise money? They might have to raise something. It's going to be family and friends for the first part. If you go to VCs too soon, it's just not patient capital, with all due respect to any venture capitalists who might be on the panel with me. It's not always patient capital, and that's the problem. It leads to conflict and it could ruin a company.
So I would just say more of the same is needed. You're doing it well already, really. It's just focusing it and making it clearer.